Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03532217

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Metastatic Hormone-Sensitive Prostate Cancer Clinical Trial

Official title:
A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Clinical Trial Summary

This study study aims to elucidate the immune responses to a shared antigen vaccine (PROSTVAC) and tumor specific antigens generated DNA vaccine in combination with checkpoint blockade using nivolumab (anti-PD-1), and ipilimumab (anti-CTLA-4). Additionally, the investigators will study the impact of the combination immunotherapy on peripheral T cell activation, as well as immune response in the tumor microenvironment. Finally, the investigators will evaluate the safety and tolerability to this novel personalized immunotherapy in combination with checkpoint blockade.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03532217
Study type Interventional
Source Washington University School of Medicine
Contact
Status Completed
Phase Phase 1
Start date September 14, 2018
Completion date July 25, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT05381311 - Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
Active, not recruiting NCT00309985 - Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Phase 3
Active, not recruiting NCT05059236 - A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. Phase 2
Completed NCT02799602 - Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer Phase 3
Not yet recruiting NCT06134271 - Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer Phase 2
Active, not recruiting NCT04934722 - Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension Phase 3
Not yet recruiting NCT06334120 - An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
Recruiting NCT05901649 - A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
Withdrawn NCT03343977 - Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Phase 1/Phase 2
Active, not recruiting NCT04191096 - Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) Phase 3
Active, not recruiting NCT03879122 - A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer Phase 2/Phase 3